Valuation: Immutep Limited

Market Cap 76.63M 53.2M 46.54M 42.92M 39.71M 75.37M 5.08B 514M 201M 2.49B 200M 195M 8.64B P/E 2026 *
-1.32x
P/E 2027 * -1.88x
Enterprise Value 11.54M 8.01M 7.01M 6.47M 5.98M 11.35M 765M 77.42M 30.35M 376M 30.09M 29.43M 1.3B EV / Sales 2026 *
0.67x
EV / Sales 2027 * -0.2x
Free-Float
96.98%
Yield 2026 *
-
Yield 2027 * -
1 day-1.89%
1 week-8.77%
Current month-1.89%
1 month+8.33%
3 months+15.56%
6 months-88.31%
Current year-87.47%
1 week 0.05
Extreme 0.051
0.06
1 month 0.04
Extreme 0.044
0.06
Current year 0.03
Extreme 0.028
0.47
1 year 0.03
Extreme 0.028
0.47
3 years 0.03
Extreme 0.028
0.48
5 years 0.03
Extreme 0.028
0.71
10 years 0.03
Extreme 0.028
0.72
Manager TitleAgeSince
Chief Executive Officer 53 2014-07-08
Director of Finance/CFO - 2018-02-28
Chief Tech/Sci/R&D Officer - 2025-06-30
Director TitleAgeSince
Director/Board Member 53 2014-07-08
Chairman 76 2017-11-16
Director/Board Member 57 2014-02-11
Date Insider Type Main position Quantity % Market Cap.
03-17Other

Chief Technology Officer

14,224,374 0.9652%
03-17Other

Chairman

3,091,623 0.2098%
03-17Other

Chief Executive Officer

18,477,395 1.2538%
Change 5-day change 1-year change 3-year change Capi.($)
-1.89%-8.77%-79.20%-83.23% 53.99M
+1.68%+3.19%+3.55%+10.22% 49.42B
+1.68%+1.82%+400.19%+608.10% 40.34B
+1.83%+0.23%+28.08%-5.43% 34.01B
+0.35%+2.02%+18.77%+57.73% 33.56B
-2.09%-0.80%+3.56%+33.56% 26.84B
+0.20%+0.97% - - 17.22B
+0.19%-4.44%+66.01%+120.36% 15.19B
-23.85%-20.86%+51.14%+54.94% 13.96B
+2.59%-0.49%+15.24%+20.83% 13.36B
Average -1.95%+0.04%+56.37%+90.79% 24.4B
Weighted average by Cap. -0.53%+0.90%+87.84%+134.78%

Financials

2026 *2027 *
Net sales 17.23M 11.96M 10.47M 9.65M 8.93M 16.95M 1.14B 116M 45.31M 561M 44.91M 43.94M 1.94B 3.15M 2.19M 1.91M 1.77M 1.63M 3.1M 209M 21.14M 8.29M 103M 8.21M 8.04M 355M
Net income -58.54M -40.64M -35.55M -32.79M -30.34M -57.58M -3.88B -393M -154M -1.91B -153M -149M -6.6B -47.05M -32.67M -28.58M -26.35M -24.38M -46.28M -3.12B -316M -124M -1.53B -123M -120M -5.3B
Net Debt -65.09M -45.19M -39.53M -36.45M -33.73M -64.02M -4.31B -437M -171M -2.12B -170M -166M -7.34B -77.26M -53.64M -46.92M -43.27M -40.04M -75.99M -5.12B -518M -203M -2.51B -201M -197M -8.71B
Logo Immutep Limited
Immutep Limited is an Australia-based late-stage biotechnology company. The Company is focused on developing novel immunotherapies for cancer and autoimmune disease. It is focused on advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Its lead clinical candidate is eftilagimod alfa (efti or IMP321) for the treatment of different types of cancers. Efti is the Company’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Its second in-house product candidate (IMP761) which is in clinical development for the treatment of autoimmune disease, a third product candidate, IMP731, a depleting antibody that could remove T cells involved in autoimmunity.
Employees
31
Date Price Change Volume
26-07-09 A$0.0520 -1.89% 3,911,401
26-07-08 A$0.0530 -3.64% 7,019,166
26-07-07 A$0.0550 0.00% 19,487,912
26-07-06 A$0.0550 0.00% 2,914,012
26-07-03 A$0.0550 -1.79% 5,503,476
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
4
Last Close Price
0.0520AUD
Average target price
0.1033AUD
Spread / Average Target
+98.71%

Quarterly revenue - Rate of surprise